Snapshot from Aug 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Cardiol Therapeutics Fireside Chat...
Business conference participation

Cardiol Therapeutics Fireside Chat at Canaccord Conference

Analysis based on 6 articles · First reported Aug 05, 2026 · Last updated Aug 05, 2026

Sentiment
10
Attention
0
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement is a routine corporate communication with minimal direct market impact. It may slightly increase visibility and investor interest in Cardiol Therapeutics, but no material financial or operational changes are expected.

Biotechnology Pharmaceuticals
Event Summary

Cardiol Therapeutics Inc., a late-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease, announced on August 5, 2026, that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT. The event will be held at the InterContinental Boston Hotel and will be webcast live. The company will discuss its lead drug candidate CardiolRx, which is being evaluated in the pivotal Phase III MAVERIC trial for recurrent pericarditis, and its development of CRD-38 for inflammatory heart disease. The United States — Food and Drug Administration has granted Orphan Drug Designation to CardiolRx for pericarditis. This participation is a routine investor relations activity, providing an opportunity for the company to present its pipeline and clinical progress to the investment community.

Key Actions
20 Cardiol Therapeutics announced participation
Entities Involved
stock
Cardiol Therapeutics
Cardiol Therapeutics is the subject of the announcement, participating in the conference to present its clinical programs. This is a routine investor relations activity with no expected material impact on its stock.
Importance 100.0 Sentiment 10.0
stock
Canaccord Genuity
Canaccord Genuity is hosting the conference where Cardiol Therapeutics will present. This is a standard event for the investment bank, with no significant impact.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA previously granted Orphan Drug Designation to CardiolRx, which is mentioned in the context of the company's pipeline. No new regulatory action is announced.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Cardiol Therapeutics is listed. The announcement does not affect the exchange.
Importance 5.0 Sentiment 0.0
exch
Toronto Stock Exchange
Toronto Stock Exchange is the other exchange where Cardiol Therapeutics is listed. No impact from this announcement.
Importance 5.0 Sentiment 0.0
cnt
United States
The United States is the location of the conference and the market where Cardiol Therapeutics operates. No direct impact from this announcement.
Importance 5.0 Sentiment 0.0
Relationships
Canaccord Genuity related ↔ Nasdaq
United States — Food and Drug Administration related ↔ Nasdaq
United States — Food and Drug Administration related ↔ United States
Nasdaq related ↔ Toronto Stock Exchange
Nasdaq related ↔ United States
Toronto Stock Exchange related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.